At quarter end, we had $323 million in cash and short-term investments on the balance sheet ... that personalized semaglutide is both clinically necessary for some patients because of the side ...

Our disease and product education efforts are ... estimate of -- what percentage of your patients are on GLP-1s? How do you expect this to change as semaglutide gains label expansion into MASH?

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Semaglutide effectively treats liver disease in two thirds of patients, new research has found.

Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.

Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

and inconvenience for many patients. Sublingual administration offers a potential alternative to both the approved injectable semaglutide (Ozempic and Wegovy) and the oral form (Rybelsus ...

“The liver actually starts looking substantially better under the microscope in these patients,” noted Sanyal. The researchers also found that 36.8% of the semaglutide group saw improvements ...

Artificial intelligence (AI) tools significantly improve the readability of online patient education materials (PEMs), making them more accessible, a new study shows. Artificial intelligence (AI ...

Injectable medications, while bypassing the gastrointestinal tract, can cause discomfort, needless anxiety, and inconvenience for many patients. Sublingual administration offers a potential ...